Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
87 hedge funds and large institutions have $360M invested in Avadel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
14% more capital invested
Capital invested by funds: $316M → $360M (+$44.6M)
4% more funds holding
Funds holding: 84 → 87 (+3)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
97% less call options, than puts
Call options by funds: $37K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$17.8M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
+$4.25M |
| 3 |
AC
Armistice Capital
New York
|
+$3.29M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.94M |
| 5 |
Morgan Stanley
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$6.2M |
| 2 |
Millennium Management
New York
|
-$5.83M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.96M |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$3.53M |
| 5 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$2.42M |
AVDL Hedge Fund Activity: Q3 2016 in Review
87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2016, worth a combined $360M — up 14% from $316M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AVDL positions and 4 closed out — a net gain of 3 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $17.8M. The largest seller was J. Goldman & Co, cutting an estimated $6.2M.
- 87 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2016, up from 84 in Q2 2016.
- Funds reported $360M of Avadel Pharmaceuticals stock for Q3 2016, up 14% quarter-over-quarter.
- 7 funds opened new Avadel Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +3 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2016 was Perceptive Advisors, an estimated $17.8M added.
- The largest Avadel Pharmaceuticals seller in Q3 2016 was J. Goldman & Co, an estimated $6.2M sold.
Based on aggregated 13F filings for Q3 2016.